McKinsey

Gen AI is rapidly emerging as a strategic growth lever for biopharma, with an estimated $4–7 billion in annual value tied to operational efficiency, quality gains, and cost reduction across the value chain. For small-to-mid pharma, the most relevant opportunities sit in “novel” use cases like shop floor copilots, smart deviation management, product and process intelligence, and supply chain copilots — each capable of compressing timelines, reducing deviations and write-offs, and freeing talent for higher-value work. Responsory’s insight: Real commercial impact requires more than use cases. Leaders need strong data foundations, governance frameworks, and operational alignment to address risks like hallucinations, IP exposure, bias, and regulatory scrutiny — transforming gen AI into a trusted driver of launch readiness and brand performance.

View article